Inaugural Leveraged Finance Fights Melanoma London Event Raises £1.4 Million for Research
- Editor
- Feb 4
- 2 min read
What's Happening: The leveraged finance and private equity communities came together on January 29, 2025, for the first-ever Leveraged Finance Fights Melanoma (LFFM) London benefit. The event, held at The National Gallery, raised £1.4 million to support the Melanoma Research Alliance's investments in UK-based melanoma research.
The Key Moves:
Over 600 attendees participated in the inaugural LFFM London event.
The £1.4 million raised will support MRA's investments in UK-based scientists pursuing melanoma research.
This event marks LFFM's expansion into an international platform, building on its success in New York City.
By The Numbers :
LFFM has raised more than £22 million for MRA's melanoma research agenda since its founding in 2011.
The event was co-chaired by five industry leaders and supported by a host committee of 20 executives.
The evening was sponsored by numerous industry giants, including Global LFFM Partners, Platinum, Gold, Preferred, and Advocate sponsors.
Key Quotes:
"This expansion reflects the global commitment of the leveraged finance and private equity communities in driving innovation in cancer research," said Jeff Rowbottom, LFFM co-founder and MRA Board member.
"The £1.4M raised by LFFM London will have a transformative impact on our mission," said Stephanie Kauffman, president of the Melanoma Research Alliance.
"This generous support allows us to continue our investments in brilliant UK-based researchers providing them with crucial resources they need to push the boundaries of melanoma research," added Kauffman.
The Bottom Line: The inaugural LFFM London event demonstrates the leveraged finance and private equity communities' commitment to advancing melanoma research on a global scale. By raising £1.4 million, the event will significantly contribute to MRA's efforts in funding UK-based scientists and accelerating lifesaving discoveries in melanoma treatment and prevention.
Comments